The group's principal activities include integrated development of pharmaceutical products for human use. The group's three main business segments: basis research, preclinical development, manufacture and release of its products; design, management and control of clinical trials; and sales and marketing. Main productline includes human healthcare products to treat chronic respiratory and autoimmune diseases. Products includes medicines for the management of asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD); treatment of multiple sclerosis; and rheumatoid arthritis. In 2005, the group has applied to market Aridol™ in Australia and Europe, it was granted Orphan Drug status for Bronchitol™ by US FDA. In 2005, the group listed its ADRs on NASDAQ National Market. In 2004, the group raised capital of $19.8 million & established Level One ADR program. In 2003 its ASX IPO raised $25 million.
Aridol & Bronchitol are patented, dry powder formulation of mannitol delivered to the lungs through an inhaler.
